Printer Friendly

GW Pharmaceuticalsa[euro](tm) Sativex receives regulatory approval in Switzerland.

M2 EQUITYBITES-November 28, 2013-GW Pharmaceuticalsa[euro](tm) Sativex receives regulatory approval in Switzerland(C)2013 M2 COMMUNICATIONS

Biopharmaceutical company GW Pharmaceuticals plc (Nasdaq: GWPH) (AIM: GWP) announced on Wednesday the receipt of regulatory approval for its prescription medicine Sativex in Switzerland.

The company said a full marketing authorisation has been granted by the Swissmedic authorities in the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications.

According to the company, the launch timing is dependent on completion of pricing and reimbursement procedures. Sativex will be commercialised in Switzerland by GW's European partner, Almirall S.A.

Currently, Sativex is approved for use in the treatment of MS spasticity in 23 countries, including 17 countries in Europe. Also, the medicine is currently available on prescription in the UK, Spain, Germany, Canada, Denmark, Norway, Israel, Austria, Poland, Sweden, Italy and Finland with launches currently in preparation for a further eight European countries, as well as Australia, New Zealand and Kuwait.

((Comments on this story may be sent to>PDNovember 28, 2013>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 28, 2013
Previous Article:Vince Holding closes its IPO of USD10m common stock at USD20.00 per share and exercise of underwritersa[euro](tm) option.
Next Article:Forestar Group closes its USD144.8m 6% tangible equity units offering.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |